MannKind Corp (NASDAQ
NASDAQ
The Nasdaq Stock Market is an American stock exchange. It is the second-largest stock exchange in the world by market capitalization, behind only the New York Stock Exchange located in the same city. The exchange platform is owned by Nasdaq, Inc., which also owns the Nasdaq Nordic and Na…
What is MannKind's (MannKind) stock price potential in the next year?
6 brokerages have issued 1 year target prices for MannKind's shares. Their forecasts range from $5.00 to $8.00. On average, they anticipate MannKind's stock price to reach $6.30 in the next year. This suggests a possible upside of 66.2% from the stock's current price.
Will MannKind stock outperform or underperform the S&P 500 over the long term?
Vote “Outperform” if you believe MNKD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MNKD will underperform the S&P 500 over the long term. You may vote once every thirty days. MannKind does not currently pay a dividend. MannKind does not have a long track record of dividend growth.
Does MannKind have an upside of 66% from current price?
According to analysts' consensus price target of $6.30, MannKind has a forecasted upside of 66.2% from its current price of $3.79. MannKind has only been the subject of 3 research reports in the past 90 days. MannKind has received 563 “outperform” votes.
Who are the insiders of MannKind?
Company insiders that own MannKind stock include Alejandro Galindo, David Thomson, Michael Castagna, Steven B Binder, Stuart A Tross and Stuart A Tross. View institutional ownership trends for MannKind. Which institutional investors are selling MannKind stock?
See more
Is MannKind a good stock to buy?
MannKind has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
What does MannKind Corporation do?
As a biopharmaceutical company focused on creating cutting-edge therapies and technologies for patients with diabetes and orphan lung diseases, MannKind is on a mission to help people take control of their health.
Who founded mannkind?
Alfred E. MannMannKind Corporation / FounderAlfred E. Mann, also known as Al Mann, was an American physicist, inventor, entrepreneur, and philanthropist. Wikipedia
Is afrezza still on the market?
No. Afrezza insulin is not discontinued and is available by prescription for adults with type 1 or type 2 diabetes.
3.4 Analyst's Opinion
MannKind has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Is MannKind a buy right now?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MannKind in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MannKind stock. View analyst ratings for MannKind or view top-rated stocks.
How has MannKind's stock price been impacted by COVID-19 (Coronavirus)?
MannKind's stock was trading at $1.10 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MNKD shares have increased by 247.3% and is now trading at $3.82. View which stocks have been most impacted by COVID-19.
When is MannKind's next earnings date?
MannKind is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022. View our earnings forecast for MannKind.
How can I listen to MannKind's earnings call?
MannKind will be holding an earnings conference call on Thursday, February 24th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.
How were MannKind's earnings last quarter?
MannKind Co. (NASDAQ:MNKD) announced its earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.03. The biopharmaceutical company had revenue of $22.21 million for the quarter, compared to the consensus estimate of $20.54 million.
What price target have analysts set for MNKD?
5 analysts have issued 12 month price objectives for MannKind's shares. Their forecasts range from $5.00 to $8.00. On average, they expect MannKind's stock price to reach $6.13 in the next twelve months.
